{"nctId":"NCT02607735","briefTitle":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy","startDateStruct":{"date":"2015-11-11","type":"ACTUAL"},"conditions":["Hepatitis C"],"count":416,"armGroups":[{"label":"SOF/VEL/VOX (Primary Study)","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL/VOX"]},{"label":"Placebo (Primary Study)","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo"]},{"label":"SOF/VEL/VOX (Deferred Treatment Substudy)","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL/VOX"]}],"interventions":[{"name":"SOF/VEL/VOX","otherNames":["Vosevi®","GS-7977/GS-5816/GS-9857"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* HCV RNA ≥ 10\\^4 IU/mL at screening\n* Chronic HCV infection (≥ 6 months)\n* Treatment experienced with a direct acting antiviral medication for HCV\n* Use of protocol specified methods of contraception\n\nKey Exclusion Criteria:\n\n* Current or prior history of clinically significant illness that may interfere with participation in the study\n* Screening ECG with clinically significant abnormalities\n* Laboratory results outside of acceptable ranges at screening\n* Pregnant or nursing female\n* Chronic liver disease not caused by HCV\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) (Primary Study)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event (Primary Study)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4) (Primary Study)","description":"SVR4 was defined as HCV RNA \\< LLOQ at 4 weeks after stopping study treatment, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ On Treatment (Primary Study)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA (Primary Study)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.20","spread":"0.733"},{"groupId":"OG001","value":"0.02","spread":"0.300"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.81","spread":"0.704"},{"groupId":"OG001","value":"0.02","spread":"0.322"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.07","spread":"0.677"},{"groupId":"OG001","value":"-0.01","spread":"0.441"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.11","spread":"0.678"},{"groupId":"OG001","value":"0.05","spread":"0.434"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.10","spread":"0.690"},{"groupId":"OG001","value":"0.03","spread":"0.430"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24) (Primary Study)","description":"SVR24 was defined as HCV RNA \\< LLOQ at 24 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure (Primary Study)","description":"Virologic failure is defined as:\n\n* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA LLOQ while on treatment), or\n  * Rebound (confirmed 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA LLOQ at last on-treatment visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 4, 12, and 24 Weeks After Discontinuation of Therapy (Deferred Treatment Substudy)","description":"SVR4, SVR12 and SVR24 was defined as HCV RNA \\< LLOQ at 4, 12 and 24 weeks after stopping study treatment, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ On Treatment (Deferred Treatment Substudy)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA (Deferred Treatment Substudy)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.30","spread":"0.626"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.93","spread":"0.602"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.16","spread":"0.512"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.20","spread":"0.532"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.20","spread":"0.532"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure (Deferred Treatment Substudy)","description":"Virologic failure is defined as:\n\n* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA LLOQ while on treatment), or\n  * Rebound (confirmed 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA LLOQ at last on-treatment visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":263},"commonTop":["Headache","Fatigue","Diarrhoea","Nausea","Asthenia"]}}}